WeGovy will remain in limited supply into 2024.
Share:
More In Science
AstraZeneca: U.S. Data Shows Vaccine Effective for All Adults
AstraZeneca says its COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease in final-stage U.S. testing, including in older adults.
CDC Changes School Guidance, Allowing Desks to Be Closer
U.S. health officials are relaxing social distancing recommendations for schools, now saying students can sit as close as 3 feet to each other in classrooms.
Happiness Report 2021: World Shows Resilience in Face of COVID-19
The editors of the 2021 World Happiness Report found that longer-term satisfaction didn't change much despite the pandemic. Finland placed first for the fourth consecutive year. The U.S. slipped from 18th to 19th place.
Scientist Behind Coronavirus Shot Says Next Target Is Cancer
BioNTech co-founder Ozlem Tureci said she and her colleagues have all received the vaccine the company developed together with Pfizer. and said that the mRNA technology will be used to fight cancer “within only a couple of years.”
Teachers by Day, Vaccine Hunters by Night: How One Group Is Helping the COVID Effort
Cheddar talks to a group of Maryland teachers who took on the added task of hunting down vaccine appointments on behalf of the local seniors and Spanish-speaking populace.
NASA Completes Engine Test Firing of Moon Rocket on 2nd Try
NASA has completed an engine test firing of its moon rocket, after the first attempt in January ended prematurely.
Scientists in U.S. and Canada Set to Battle Murder Hornets
Scientists in the U.S. and Canada are opening new fronts in the war against so-called murder hornets as the giant insects begin establishing nests this spring.
Israeli Experts Announce Discovery of More Dead Sea Scrolls
Israeli archaeologists have announced dozens of newly discovered Dead Sea Scroll fragments bearing a biblical text.
EU Regulator 'Convinced' AstraZeneca Benefit Outweighs Risk
With COVID cases rising in many places, governments are facing the dilemma to push on with a vaccine that is known to save lives or suspend use of AstraZeneca over reports of dangerous blood clots in a few recipients.
